A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

Exclusion criteria

• . Any suspicat screening ion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be clinically significant) in participants;
• . Blood donation or blood loss not less than 400 mL within 12 weeks before screening;
• . Drug administration that change the activity of liver enzymes within 28 days prior to screening;
• . Receipt of another investigational drug or device within 3 months before first dosing (interventional treatment);
• . Clinically significant electrocardiogram (ECG) abnormalities on screening ECG;
• . TdP high-risk factors (hypokalemia, hypomagnesemia, decompensated heart failure and acute myocardial infarction), and QTc interval above 450 msec in participants (judged by investigator based on actual screening conditions);
• . Pregnant (positive pregnancy test), recently ready to conceive, or lactating female;
• . Clinically significant lab examination abnormalities, or other clinically significant diseases discovered within 12 months before screening, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrinological, tumor, pulmonary, immune, mental, or cardiovascular and cerebrovascular diseases;